Cadaveric Human Growth Hormone-Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States
- PMID: 40439459
- PMCID: PMC12123925
- DOI: 10.3201/eid3106.241519
Cadaveric Human Growth Hormone-Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States
Abstract
We report a case of iatrogenic Creutzfeldt-Jakob disease (iCJD) after a 48.3-year incubation period in a patient treated with cadaveric human growth hormone. iCJD was pathologically confirmed; genetic analysis was negative for pathogenic mutations. Clinicians should consider iCJD in patients with progressive neurologic signs who had received cadaveric human growth hormone treatment.
Keywords: CJD; Creutzfeldt-Jakob disease; PrPSc proteins; United States; human growth hormone; myoclonus; prions and related diseases; sporadic.
Figures


References
-
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. National Hormone & Pituitary Program (NHPP): information for people treated with pituitary human growth hormone [cited 2024 Jul 28]. https://www.niddk.nih.gov/health-information/endocrine-diseases/national...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical